Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRedx Pharma Plc

Redx Pharma Plc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None GBX 0.00(0%)
Last update at 2024-06-04T03:29:59.866282Z
Market Cap
89.47M

Momentum Score

…

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops RXC008, a gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the RAS-RAF-MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
21.02
Low
70.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
4.20M
Revenue Per Share
0.01
Gross Profit TTM
18.69M
Debt / Equity
5.27
ROE
-180.80%
Net Debt
-0.41M
ROCE
-351.39%
Diluted EPS TTM
-0.10

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Income before tax -17.80M -21.44M -9.17M -6.33M -10.15M
Net income -18.00M -21.58M -9.21M -4.32M -8.85M
Selling general administrative 10.23M 6.46M 0.05M 0.05M 0.22M
Gross profit 18.69M 10.04M 5.68M 2.78M 0.13M
Reconciled depreciation 0.89M 0.63M 0.67M 0.09M 0.16M
Ebit -16.27M -19.75M -8.27M -7.19M -10.14M
Ebitda -15.19M -19.10M -7.60M -7.09M -9.98M
Depreciation and amortization 1.07M 0.65M 0.67M 0.10M 0.16M
Operating income -16.27M -19.75M -8.27M -7.19M -9.20M
Other operating expenses 37.25M 29.78M 13.96M 10.32M 9.33M
Interest expense 1.73M 1.71M 0.97M 0.10M 0.00M
Tax provision 0.20M 0.13M 0.04M -2.02M -1.30M
Interest income 0.19M 0.01M 0.01M 0.01M 0.02M
Net interest income -1.54M -1.70M -0.97M -0.09M 0.02M
Income tax expense 0.20M 0.13M 0.04M -2.02M -1.30M
Total revenue 18.69M 10.04M 5.68M 3.13M 0.13M
Total operating expenses 37.25M 29.78M 13.96M 9.97M 9.33M
Cost of revenue - - 0.00M 0.35M 9.24M
Total other income expense net -1.54M -1.70M -0.89M 0.86M -0.95M
Net income from continuing ops -18.00M -21.58M -9.21M -4.32M -8.85M
Net income applicable to common shares -18.00M -21.58M -9.21M -4.32M -8.85M
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 25.64M 62.48M 39.55M 33.59M 6.36M
Intangible assets - 0.09M 0.10M 0.10M 0.11M
Other current assets - 5.52M 6.26M 1.96M 2.10M
Total liab 22.28M 29.16M 26.41M 30.90M 4.87M
Total stockholder equity 3.35M 33.32M 13.13M 2.69M 1.49M
Other current liab 0.84M 4.89M 4.32M 7.07M 0.95M
Common stock 3.35M 3.35M 2.75M 1.95M 1.26M
Capital stock 3.35M 3.35M 2.75M 1.95M 1.26M
Retained earnings -113.83M -81.31M -64.23M -42.21M -34.14M
Good will - 0.31M 0.31M 0.31M 0.31M
Cash 18.09M 53.85M 29.55M 27.51M 3.70M
Total current liabilities 21.01M 27.20M 9.59M 10.93M 4.87M
Net debt -0.41M -35.55M -12.16M -7.04M -3.24M
Short term debt 16.41M 16.35M 0.57M 0.50M 0.47M
Short long term debt 15.73M 15.73M - 0.00M 0.47M
Short long term debt total 17.68M 18.30M 17.40M 20.47M 0.47M
Other stockholder equity 113.83M 111.28M 74.61M 42.95M 34.37M
Property plant equipment - 2.70M 3.33M 3.71M 0.13M
Total current assets 23.30M 59.38M 35.81M 29.47M 5.81M
Net tangible assets - 32.92M 12.73M 2.28M 1.07M
Net receivables 5.21M 5.50M 6.26M 0.84M 1.43M
Long term debt - 0.00M 14.25M 16.76M -
Accounts payable 3.76M 5.96M 4.70M 3.36M 3.44M
Accumulated other comprehensive income - - - -1.79M -1.14M
Common stock total equity - - - 1.95M 1.26M
Non currrent assets other - - 0.41M - 0.55M
Non current assets total 2.33M 3.10M 3.73M 4.12M 0.55M
Capital lease obligations 1.95M 2.57M 3.15M 3.71M -
Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Investments -0.24M -0.75M -0.06M 0.03M -0.11M
Change to liabilities -5.59M -1.41M 7.33M -0.71M -8.96M
Total cashflows from investing activities -0.24M -0.75M -0.06M 0.03M -0.11M
Net borrowings -0.82M -0.79M 22.89M 1.00M 1.00M
Total cash from financing activities 32.98M 24.14M 23.47M 1.87M -0.05M
Net income -18.00M -21.58M -9.21M -4.32M -8.85M
Change in cash 24.30M 2.04M 23.81M -2.77M -17.34M
Begin period cash flow 29.55M 27.51M 3.70M 6.47M 23.81M
End period cash flow 53.85M 29.55M 27.51M 3.70M 6.47M
Total cash from operating activities -8.47M -21.38M 0.40M -4.67M -17.18M
Issuance of capital stock 34.57M 25.98M 2.10M - 0.00M
Depreciation 0.89M 0.63M 0.67M 0.09M 0.16M
Other cashflows from investing activities - - 0.00M 0.06M 0.02M
Change to account receivables 7.63M -4.65M -0.91M 0.45M 0.57M
Sale purchase of stock - 25.98M 2.10M - -
Other cashflows from financing activities -1.59M -1.84M 26.37M 1.87M -0.05M
Change to netincome 6.61M 5.63M 2.52M -0.18M -0.10M
Capital expenditures 0.26M 0.75M 0.06M 0.03M 0.13M
Change in working capital 2.04M -6.07M 6.42M -0.27M -8.39M
Stock based compensation 4.37M 3.79M 0.57M 0.04M -
Other non cash items 2.25M 1.70M 0.96M -0.93M -0.39M
Free cash flow -8.73M -22.13M 0.34M -4.70M -17.31M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GNS
Genus PLC		 18.00
0.78%		 2340.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 10.60
4.93%		 225.60 - - 4.71 2.50 4.23 -8.89
OXB
Oxford BioMedica PLC		 5.00
0.95%		 532.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 -1.00
1.60%		 61.50 - - 2849.46 1929.84 2525.51 -12.04

Profile*

Redx Pharma Plc

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops RXC008, a gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the RAS-RAF-MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.

Alderley Park, Macclesfield, United Kingdom, SK10 4TG

44 16 2546 9900

https://www.redxpharma.com

65

Name Title Year Born
Ms. Lisa Mary Whewell Anson CEO & Exec. Director 1970
Dr. James Mead Chief Operating Officer 1978
Mr. Peter J. Collum Chief Financial Officer NA
Dr. Richard Armer Chief Scientific Officer NA
Dr. Karl Hard Ph.D. Head of Investor Relations 1962
Ms. Claire Solk Gen. Counsel & Company Sec. NA
Ms. Caitlin Pearson Head of Communications NA
Dr. Jane Robertson Chief Medical Officer NA
Dr. Cliff Jones Sr. VP of Chemistry, DMPK & Intellectual Property NA
Dr. Caroline Phillips Sr. VP of Biology NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DRUG
CAD 32.00
+23.08%
CHR
CAD 35.50
+7.80%
HG
CAD 4.77
+7.19%
QTWO
CAD 1.73
+7.14%
PET
CAD 23.03
+7.02%
MUX
CAD 18.80
-17.69%
URE
CAD 0.96
-15.04%
WELL
CAD 3.62
-14.82%
ITH
CAD 2.01
-10.67%
SGML
CAD 7.52
-9.94%

Equity Sectors*

  • Basic Materials

    -3.56%

  • Communication Services

    +0.11%

  • Consumer Cyclical

    -0.57%

  • Consumer Defensive

    -0.30%

  • Energy

    +0.19%

  • Financial Services

    -0.06%

  • Healthcare

    -0.37%

  • Industrials

    -0.81%

  • Real Estate

    -0.85%

  • Technology

    -0.12%

  • Utilities

    -0.11%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…